CAPR
NASD Capricor Therapeutics, Inc.$8.95 ↑ +0.01 (+0.11%) Trading Up from the previous close of $8.94, $0.29 below the day’s high of $9.24
- YTD change
- -68.99%
- vs 20-day SMA
- +1.14%
- vs 200-day SMA
- -60.88%
Price ranges
Price & Performance
-23.17 (-72.16%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 78.9% away from all-time highs of $42.50
- CAPR is down 69% since the beginning of the year
- CAPR is up 12% over the past 12 months
- CAPR is down 10% over the past 1 month
- 39% of all CAPR investors are betting against CAPR
CAPR reads not so good: price sits above one of the two key moving averages, the 12-month move is +12.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- +4.43%
- vs 8-day SMA
- +1.37%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMDâ€), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.